Association between genetic polymorphisms of interleukin-1 B and interleukin-1 receptor antagonist genes and susceptibility to osteoarthritis

doi:10.3877/cma.j.issn.1674-134X.2018.04.013

Abstract

Abstract:

Objective

To investigate the association between genetic polymorphisms of interleukin -1 B (-31C/T、-511C/T、+ 3954C/T) and interleukin -1 receptor antagonist (IL-1ra)(gene code: IL-1RN) and susceptibility to knee osteoarthritis patients from Qingdao area of China.

Methods

A case-control study was conducted in 216 knee osteoarthritis patients from Jiaozhou Central Hospital of Qingdao; previous knee trauma, rheumatoid arthritis and other medical diseases were excluded and 233 healthy controls were matched in age and sex. The single nucleotide polymerphisms (SNPs) at positions IL-1B-31C/T、-511C/T、+ 3954C/T and IL-1RN were analyzed using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) and association between genotypes and risk of osteoarthritis were determined by logistic regression analysis.

Results

An increased frequency of IL-1B -511CT and IL-1B + 3954CT genotypes was noted in osteoarthritis patients and the difference was statistically significant compared with the control group [IL-1B-511CT χ²=2.034, P=0.026; IL-1B+ 3954CT χ²=5.526, P=0.017). No IL-1B + 3954TT genotype was found in this study. In a logistic regression analysis, IL-1B -511CT and IL-1B + 3954CT genotypes were associated with an odds ratio for osteoarthritis [IL-1B-511CT, OR=1.89, 95%CI(0.56, 1.39), P=0.026; IL-1B+ 3954CT, OR =2.51, 95%CI (1.18, 5.35), P=0.017]. No significant difference was found in the allelic or genotypic frequencies of IL-1B-31C/T or IL-1 RN between the osteoarthritis patients and the controls.

Conclusion

IL-1B-511CT and + 3954CT genotypes may associate with an increased risk of knee osteoarthritis, while there is no association between genetic polymorphisms of IL-1B-31C/T and IL-1 RN*2 and susceptibility to knee osteoarthritis.

Key words: Osteoarthritis, Polymorphism, genetic, Interleukins

Chengkai Shen, Xichun Zhao, Daitong Sun, Junqiang Zhao, Yan Chen, Haijun Zhao, Chengyu Lyv. Association between genetic polymorphisms of interleukin-1 B and interleukin-1 receptor antagonist genes and susceptibility to osteoarthritis[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2018, 12(04): 516-522.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgjwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-134X.2018.04.013

https://zhgjwkzz.cma-cmc.com.cn/EN/Y2018/V12/I04/516

Figures/Tables 8

References 30

[1]	Peach CA, Carr AJ, Loughlin J. Recent advances in the genetic investigation of osteoarthritis[J]. Trends Mol Med, 2005, 11(4):186-191.
[2]	Garstang SV, Stitik TP. Osteoarthritis: epidemiology, risk factors, and pathophysiology[J]. Am J Phy Med Rehabil, 2006, 85(11):S2-S11.
[3]	Steinmeyer J. Cytokines in osteoarthritis-current status on the pharmacological intervention[J]. Front Biosci, 2004, 9(9):575-580.
[4]	Loughlin J. The genetic epidemiology of human primary osteoarthritis: current status[J]. Expert Rev Mol Med, 2005, 7(9):1-12.
[5]	Towne JB. IL-1F6，IL-1F8，and IL-1F9，signal throughIL-1RrD2 andIL-1RAcP to activatethel athway1eading to NF kappaB and MAP[J]. Eiol Cbem, 2014, 279(14):13677-13688.
[6]	He W, Pelletier JP, Martel-Pelletier J, et al. Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines[J]. J Rheumatol, 2002, 29(3):546-553.
[7]	Hajizadeh YS, Emami E, Nottagh M, et al. Effects of interleukin-1 receptor antagonist (IL-1Ra) gene 86 bp VNTR polymorphism on recurrent pregnancy loss: a case-control study[J]. Horm Mol Biol Clin Investig, 2017, 30(3):1868-1891.
[8]	Kayar NA, Alptekin NÖ, Erdal ME. Interleukin-1 receptor antagonist gene polymorphism, adverse pregnancy outcome and periodontitis in Turkish women[J]. Arch Oral Biol, 2015, 60(12):1777-1783.
[9]	Kristy LW, Jevseva DS. AAOS clinical practice guideline：surgical management of osteoarthritis of the knee[J]. J Am Acad Orthop Surg, 2016, 24(8):e94-e96.
[10]	Bhattacharya R, Kumar V, Safawi E, et al. The knee skyline radiograph: its usefulness in the diagnosis of patello-femoral osteoarthritis[J]. Int Orthop, 2007, 31(2):247-252.
[11]	Patel R, Dwivedi M, Mansuri MS, et al. Association of neuropeptide-Y (NPY) and interleukin-1beta (IL1B), genotype-phenotype correlation and plasma lipids with type-II diabetes[J/OL]. PLoS One, 2016, 11(10):e0164437. URL
[12]	Tabrez S, Jabir NR, Firoz CK, et al. Estimation of interleukin-1β promoter (-31 C/T and -511 T/C) polymorphisms and its level in coronary artery disease patients[J]. J Cell Biochem, 2017, 118(9):2977-2982.
[13]	Szpecht D, Gadzinowski J, Nowak I, et al. The significance of IL-1β ＋3953C>T, IL-6 -174G>C and -596G>A, TNF-α -308G>A gene polymorphisms and 86 bp variable number tandem repeat polymorphism of IL-1RN in bronchopulmonary dysplasia in infants born before 32 weeks of gestation[J]. Cent Eur J Immunol, 2017, 42(3):287-293.
[14]	Cai H, Sun HJ, Wang YH, et al. Relationships of common polymorphisms in IL-6, IL-1A, and IL-1B genes with susceptibility to osteoarthritis: a meta-analysis[J]. Clin Rheumatol, 2015, 34(8):1443-1453.
[15]	Towne JE, Crka KE, Renshaw BR, et al. Interleukin(IL)-1F6，II-1F8，and IL-1F9，signal through IL-1RrD2 and IL-1RAcP to activatethel athway1eading to NF kappaB and MAPKs[J]. J Eiol Chem, 2004, 279(14):13677-13688.
[16]	Smith AJ, Keen LJ, Billingham MJ, et al. Extended haplotypes and linkage disequilibrium in the IL1R1-IL1A-IL1B-IL1RN gene cluster: association with knee osteoarthritis[J]. Genes Immun, 2004, 5(6):451-460.
[17]	Leppävuori J, Kujala U, Kinnunen J, et al. Genome scan for predisposing loci for distal interphalangeal joint osteoarthritis: evidence for a locus on 2q[J]. Am J Hum Genet, 1999, 65(4):1060-1067.
[18]	Forster T, Chapman K, Marcelline L, et al. Finer linkage mapping of primary osteoarthritis susceptibility loci on chromosomes 4 and 16 in families with affected women[J]. Arthritis Rheum, 2004, 50(1):98-102.
[19]	Hamajima N, Matsuo K, Saito T, et al. Interleukin 1 polymorphisms, lifestyle factors, and Helicobacter pylori infection[J]. Jpn J Cancer Res, 2001, 92(4):383-389.
[20]	El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer[J]. Nature, 2000, 404(6776):398-402.
[21]	Xu CF, Lewis K, Cantone KL, et al. Effectiveness of computational methods in haplotype prediction[J]. Hum Genet, 2002, 110(2):148-156.
[22]	Meulenbelt I, Seymour AB, Nieuwland M, et al. Association of the interleukin-1 gene cluster with radiographic signs of osteoarthritis of the hip[J]. Arthritis Rheum, 2004, 50(4):1179-1186.
[23]	Hall SK, Perregaux DG, Gabel CA, et al. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein[J]. Arthritis Rheum, 2004, 50(6):1976-1983.
[24]	Moos V, Rudwaleit M, Herzog V, et al. Association of genotypes affecting the expression of interleukin-1beta or interleukin-1 receptor antagonist with osteoarthritis[J]. Arthritis Rheum, 2000, 43(11):2417-2422.
[25]	Kanoh T, Hasegawa Y, Masui T, et al. Interleukin-1beta gene polymorphism associated with radiographic signs of osteoarthritis of the knee[J]. J Orthop Sci, 2008, 13(2):97-100.
[26]	Colotta F, Dower Sk, Sims JE，et al The type II'decoy' receptor: a novel regulatory pathway for interleukin-1 [J]．Immunol Tod，1994，15(12):562-566.
[27]	Peat E, Thomas D, Duncan L, et al. Clinical classification criteria for knee 0steoarthritis：performance in the general population primary care[J]. Ann Rheum Dis, 2006, 65(4):1363-1367.
[28]	Wang WZ, Guo X, Duan C, et al. Comparative analysis of gene expression profiles between the normal human cartilage and one with endemic osteoarthritis[J]. Osteoarthritis Cartilage, 2009, 17(6):83-89.
[29]	Swellam M, Mahmoud MS, Samy N, et al. Potential influence of interleukin-1 receptor antagonist gene polymorphism on knee osteoarthritis risk[J]. Dis Markers, 2010, 28(5):299-305.
[30]	王友成，刘铮，刘国华，等．TGF-β1基因C1348-T位点与膝骨关节炎的关系[J/CD]．中华关节外科杂志(电子版)，2015，9(4):500-504.

?	例数	年龄[岁，(±s)]	性别(男/女)	BMI[kg/m²，(±s)]
对照组	233	55.7±13.5	54/179	25.3±1.3
骨关节炎组	216	56.4±14.3	48/168	26.4±1.3
统计值	?	t＝1.519	χ²＝0.352	t＝2.643
P值	?	>0.05	>0.05	>0.05

?	例数	年龄[岁，(±s)]	性别(男/女)	BMI[kg/m²，(±s)]
对照组	233	55.7±13.5	54/179	25.3±1.3
骨关节炎组	216	56.4±14.3	48/168	26.4±1.3
统计值	?	t＝1.519	χ²＝0.352	t＝2.643
P值	?	>0.05	>0.05	>0.05

基因位点	?	骨关节炎组(n＝216)		对照组(n＝233)
基因位点	?	观察值	理论值	观察值	理论值
IL-1B-31 T/C	CC	49	46.3	54	50.8
?	CT	101	96.1	109	115.4
?	TT	66	73.6	70	66.8
P值	?	0.780	?	0.835	?
IL-1B-511 C/T	CC	56	53.1	59	58.3
?	CT	105	106.8	92	99.4
?	TT	55	56.1	82	75.3
P值	?	0.638	?	0.454	?
IL-1B＋ 3594 C/T	CC	169	169.5	207	205.3
?	CT	47	45	26	27.2
?	TT	0	1.3	0	0.9
P值	?	0.742	?	0.619	?
IL-1RN VNTR	1/1	158	157.5	169	168
?	1/2	45	54	50	55.8
?	2/2	8	4.5	10	9.2
?	1/3	0	0	0	0
?	1/4	5	0	4	0
P值	?	0.092	?	0.135	?

基因位点	?	骨关节炎组(n＝216)		对照组(n＝233)
基因位点	?	观察值	理论值	观察值	理论值
IL-1B-31 T/C	CC	49	46.3	54	50.8
?	CT	101	96.1	109	115.4
?	TT	66	73.6	70	66.8
P值	?	0.780	?	0.835	?
IL-1B-511 C/T	CC	56	53.1	59	58.3
?	CT	105	106.8	92	99.4
?	TT	55	56.1	82	75.3
P值	?	0.638	?	0.454	?
IL-1B＋ 3594 C/T	CC	169	169.5	207	205.3
?	CT	47	45	26	27.2
?	TT	0	1.3	0	0.9
P值	?	0.742	?	0.619	?
IL-1RN VNTR	1/1	158	157.5	169	168
?	1/2	45	54	50	55.8
?	2/2	8	4.5	10	9.2
?	1/3	0	0	0	0
?	1/4	5	0	4	0
P值	?	0.092	?	0.135	?

分组	例数	IL-1B-31 T/C [例(%)]
分组	例数	TT	CT	CC	等位基因T
骨关节炎组	216	49(22.6)	101(46.8)	66(30.6)	199(46.1)
对照组	233	54(23.2)	109(46.7)	70(30.1)	217(46.7)
OR(95%可信区间)	?	1.00	1.06(0.69，1.66)	0.95(0.57，1.59)	?
χ²值	?	?	0.216	?	?
P值	?	?	0.121^a	?	0.715^b
分组	例数	IL-1B-511 T/C [例(%)]
分组	例数	TT	CT	CC	等位基因T
骨关节炎组	216	56(25.9)	105(48.6)	55(24.5)	217(50.2)
对照组	233	59 (25.3)	92 (39.5)	82(35.2)	206(44.2)
OR(95%可信区间)	?	1.00	1.89(0.56，1.39)	0.87(0.52－1.46)	?
χ²值	?	?	2.034	?	?
P值	?	?	0.026^c	?	0.957^d
分组	例数	IL-1B＋3954T/C [例(%)]
分组	例数	TT	CT	CC	等位基因T
骨关节炎组	216	169(78.2)	47(21.8)	0	47(10.9)
对照组	233	207(88.9)	26(11.1)	0	26(5.6)
OR(95%可信区间)	?	?	1.00	2.51(1.18，5.35)	?
χ²值	?	5.526
P值	?	?	0.017^e	?	0.041^f

Please choose a citation manager

Content to export